Title |
Endothelin receptor antagonists for subarachnoid hemorrhage
|
---|---|
Published in |
Cochrane database of systematic reviews, September 2012
|
DOI | 10.1002/14651858.cd008354.pub2 |
Pubmed ID | |
Authors |
Jia Guo, Zhenghong Shi, KeHu Yang, Jin Hui Tian, Lei Jiang |
Abstract |
A subarachnoid hemorrhage (SAH) is a serious and potentially life-threatening condition where blood leaks out of blood vessels over the surface of the brain. Delayed ischemic neurological deficit (DIND) and the related feature of vasospasm, where patients experience a delayed deterioration, have long been recognized as the leading potentially treatable cause of death and disability in patients with SAH. Endothelin is a potent, long-lasting endogenous vasoconstrictor that has been implicated in the pathogenesis of DIND. Therefore, endothelin receptor antagonists (ETAs) have emerged as a promising therapeutic option for SAH-induced cerebral vasospasm. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Canada | 1 | <1% |
Unknown | 114 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 23 | 20% |
Researcher | 13 | 11% |
Student > Bachelor | 11 | 9% |
Student > Postgraduate | 9 | 8% |
Student > Ph. D. Student | 9 | 8% |
Other | 19 | 16% |
Unknown | 32 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 46 | 40% |
Nursing and Health Professions | 12 | 10% |
Neuroscience | 9 | 8% |
Social Sciences | 5 | 4% |
Agricultural and Biological Sciences | 3 | 3% |
Other | 8 | 7% |
Unknown | 33 | 28% |